Carmustine
- Generic Name
- Carmustine
- Brand Names
- Bicnu, Gliadel, Carmustine medac (previously Carmustine Obvius)
- Drug Type
- Small Molecule
- Chemical Formula
- C5H9Cl2N3O2
- CAS Number
- 154-93-8
- Unique Ingredient Identifier
- U68WG3173Y
- Background
A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index,...
- Indication
For the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas.
- Associated Conditions
- Astrocytoma, Brain Stem Gliomas, Ependymoma, High Grade Glioma: Glioblastoma (GBM), Medulloblastomas, Metastatic Brain Tumors, Mycosis Fungoides (MF), Newly Diagnosed High-Grade Glioma, Recurrent Glioblastoma Multiforme (GBM), Refractory Hodgkin Lymphoma, Refractory Multiple Myeloma, Refractory Non-Hodgkin's lymphoma
- Associated Therapies
- -
UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy
- First Posted Date
- 2004-05-27
- Last Posted Date
- 2015-11-23
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 668
- Registration Number
- NCT00083551
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences/MIRT, Little Rock, Arkansas, United States
Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Multiple Myeloma
- Conditions
- First Posted Date
- 2004-05-24
- Last Posted Date
- 2013-04-09
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 40
- Registration Number
- NCT00002552
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Combination Chemotherapy and Interferon Alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloma
- Conditions
- First Posted Date
- 2004-05-21
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- Medical Research Council
- Target Recruit Count
- 750
- Registration Number
- NCT00002599
- Locations
- 🇬🇧
Leeds Teaching Hospital Trust, Leeds, England, United Kingdom
Irinotecan Plus Carmustine in Treating Patients With Recurrent Primary Malignant Glioma
- Conditions
- First Posted Date
- 2004-05-19
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- Duke University
- Target Recruit Count
- 36
- Registration Number
- NCT00002988
- Locations
- 🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States
Carmustine Plus O6-benzylguanine in Treating Patients With Recurrent or Progressive Glioma
- Conditions
- First Posted Date
- 2004-05-03
- Last Posted Date
- 2014-08-21
- Lead Sponsor
- Duke University
- Registration Number
- NCT00005081
- Locations
- 🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2004-04-30
- Last Posted Date
- 2019-11-04
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 25
- Registration Number
- NCT00003397
- Locations
- 🇺🇸
Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia
- Conditions
- First Posted Date
- 2004-04-29
- Last Posted Date
- 2012-07-02
- Target Recruit Count
- 500
- Registration Number
- NCT00002719
- Locations
- 🇮🇹
Azienda Policlinico Umberto Primo, Rome, Italy
O6-benzylguanine and Carmustine in Treating Children With Refractory CNS Tumors
- Conditions
- Interventions
- First Posted Date
- 2004-04-27
- Last Posted Date
- 2013-02-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 36
- Registration Number
- NCT00003765
- Locations
- 🇺🇸
Emory University Hospital - Atlanta, Atlanta, Georgia, United States
🇺🇸Simmons Cancer Center - Dallas, Dallas, Texas, United States
🇺🇸Indiana University Cancer Center, Indianapolis, Indiana, United States
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Anaplastic Astrocytoma
- Conditions
- Interventions
- First Posted Date
- 2004-04-23
- Last Posted Date
- 2016-07-14
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 29
- Registration Number
- NCT00003621
- Locations
- 🇺🇸
CentraCare Clinic, Saint Cloud, Minnesota, United States
🇺🇸Altru Health Systems, Grand Forks, North Dakota, United States
🇺🇸CCOP - Ochsner, New Orleans, Louisiana, United States
S9623, Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer
- Conditions
- Interventions
- Biological: filgrastimDrug: carboplatinDrug: cyclophosphamideDrug: carmustineDrug: doxorubicin hydrochlorideDrug: cisplatinDrug: tamoxifen citrateRadiation: radiation therapyDrug: paclitaxelDrug: thiotepaProcedure: autologous bone marrow transplantationProcedure: peripheral blood stem cell transplantation
- First Posted Date
- 2004-04-22
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 602
- Registration Number
- NCT00002772
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.